On July 3, 2018, the United States Patent and Trademark Office issued patent no. 10,010,567 to Aker BioMarine, covering encapsulated krill oil with greater than 30 percent phosphatidylcholine, less than 3 percent free fatty acids, and the presence of astaxanthin esters.
“This patent is the result of our long-term patent strategy and becomes our 22nd granted U.S. krill patent. Patenting our innovation is an on-going effort that does not stop with the invention, but continues with refining a patent family based on what we learn through patent office examinations and oppositions,” says Matts Johansen, CEO at Aker BioMarine.
“With a decade left of patent life this patent will be commercially very important to Aker BioMarine, at the core of our continuously growing patent family,” Johansen adds.
Aker BioMarine’s krill products are backed up by more than a decade of science, product development, sustainable krill harvesting operations and the world’s largest krill patent portfolio.
The issuing U.S. patent belongs to the same patent family as Aker BioMarine’s European patent 2144618, which had all 27 claims upheld and reconfirmed by the European Patent Office in October 2017 after thorough opposition proceedings.
Get a full overview of the patents granted to Aker BioMarine HERE.
For more information, please contact:
Katrin Berntsen
Director Communication
katrin.berntsen@akerbiomarine.com
ph: +47 920 54 570
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. The company develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and all the way to customers around the world. Aker BioMarine is fully owned by Aker ASA, an industrial pioneer since its establishment in 1841.